EP
NPCE icon

Essential Partners’s Neuropace NPCE Stock Holding History

Essential Partners’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64 Sell
4
-27
-87% -$435 ﹤0.01% 2778
2026
Q1 		$408 Buy
+31
New +$465 ﹤0.01% 2493

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Essential Partners's NPCE Position: Q2 2026 in Review

Essential Partners reduced its Neuropace (NPCE) stake by 87% in Q2 2026, selling an estimated $435 and leaving 4 shares worth $64. The position accounts for ﹤0.01% of the portfolio, ranked #2778.

Essential Partners first reported a position in NPCE in Q1 2026 and has held it in 2 quarters since. The position peaked at $408 in Q1 2026. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Essential Partners held 4 shares of Neuropace worth $64 as of Q2 2026.
  • Essential Partners sold 27 Neuropace shares in Q2 2026, an estimated $435.
  • Neuropace made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2778 holding.
  • Essential Partners first reported a position in Neuropace in Q1 2026 and has held it in 2 quarters since.
  • Essential Partners's Neuropace position peaked at $408 in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.